Regardless of the sequential decrease in Current Liabilities, during the second quarter 2026, Quick Ratio deteriorated to 0.29 below Ainos Inc 's average Quick Ratio.

Within Major Pharmaceutical Preparations industry 407 other companies have achieved higher Quick Ratio than Ainos Inc in second quarter 2026. While Quick Ratio total ranking in the second quarter 2026 has deteriorated compared to the prior quarter from 2408 to 3087.

Explain Quick Ratio?
How much Cash & cash equivalents AIMD�s has?
What are AIMD�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

AIMD Quick Ratio	(Jun 30 2026) Q2	(Mar 31 2026) Q1	(Dec 31 2025) Q4	(Sep 30 2025) Q3	(Jun 30 2025) Q2
Y / Y Current Liabilities Change	717.44 %	316.57 %	-81.07 %	-85.93 %	-89.5 %
Y / Y Cash & cash equivalent Change	16.33 %	8.11 %	-89.28 %	-78.12 %	-84.74 %
Quick Ratio MRQ	0.29	0.45	0.57	1.94	2.03
AIMD's Total Ranking	# 3087	# 2408	# 2220	# 970	# 906
Seq. Current Liabilities Change	-22.36 %	770.93 %	25.34 %	-3.55 %	-60.43 %
Seq. Cash & cash equivalent Change	-49.92 %	580.82 %	-63.01 %	-7.76 %	-53.46 %

Quick Ratio second quarter 2026 Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 408
Healthcare Sector	# 789
Overall Market	# 3087

Quick Ratio Statistics
High	Average	Low
5.9	0.88	0
(Sep 30 2018)		(Sep 30 2014)

Financial Statements
Ainos Inc 's Current Liabilities	$ 5 Millions	Visit AIMD's Balance sheet
Ainos Inc 's Cash & cash equivalent	$ 1 Millions	Visit AIMD's Balance sheet
Source of AIMD's Sales		Visit AIMD's Sales by Geography

Cumulative Ainos Inc 's Quick Ratio

AIMD's Quick Ratio for the trailling 12 Months

AIMD Quick Ratio	(Jun 30 2026) 12 Months	(Mar 31 2026) 12 Months	(Dec 31 2025) 12 Months	(Sep 30 2025) 12 Months	(Jun 30 2025) 12 Months
Y / Y Current Liabilities TTM Growth	24.52 %	-45.83 %	-81.35 %	-58.81 %	-19.83 %
Y / Y Cash & cash equivalent TTM Growth	-54.97 %	-71.51 %	-70.17 %	-44.85 %	-3.01 %
Quick Ratio TTM	0.46	0.68	1.57	1.35	1.28
Total Ranking TTM	# 4087	# 3908	# 2955	# 3056	# 2769
Seq. Current Liabilities TTM Growth	52.36 %	140.35 %	-47.59 %	-35.12 %	-33.72 %
Seq. Cash & cash equivalent TTM Growth	3.56 %	3.95 %	-39.17 %	-31.23 %	-34.49 %

Quick ratio ranking by company, industry and sector >> Back to AIMD Financial Strength Comparisons >> Go to Compare AIMD Quick Ratio to its Competitors

On the trailing twelve months basis Due to decline in Current Liabilities in the Q2 2026 to $4.93 millions, cumulative Quick Ratio decreased to 0.46 below the Ainos Inc average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 442 other companies have achieved higher Quick Ratio than Ainos Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the first quarter 2026 from 3908 to 4087.

Explain Quick Ratio?
How much Cash & cash equivalents AIMD�s has?
What are AIMD�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Major Pharmaceutical Preparations Industry	# 443
Healthcare Sector	# 908
Within the Market	# 4087

trailing twelve months Quick Ratio Statistics
High	Average	Low
1.56	0.51	0
(Mar 31 2019)		(Sep 30 2014)

Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within Major Pharmaceutical Preparations Industry	Quick Ratio	Jun 30 2026 MRQ Cash & cash equivalent	Jun 30 2026 MRQ Current Liabilities
Nrx Pharmaceuticals Inc	0.79	$ 26.686 Millions	$ 33.874 Millions
Oncolytics Biotech Inc	0.79	$ 4.115 Millions	$ 5.225 Millions
Moleculin Biotech Inc	0.78	$ 7.262 Millions	$ 9.313 Millions
Seres Therapeutics Inc	0.78	$ 15.594 Millions	$ 20.031 Millions
Travere Therapeutics Inc	0.77	$ 117.735 Millions	$ 152.025 Millions
Arcus Biosciences Inc	0.77	$ 153.000 Millions	$ 198.000 Millions
Alkermes Plc	0.77	$ 511.529 Millions	$ 662.091 Millions
Integrated Biopharma Inc	0.77	$ 4.471 Millions	$ 5.802 Millions
Cyclerion Therapeutics Inc	0.75	$ 1.391 Millions	$ 1.843 Millions
Dar Bioscience Inc	0.75	$ 12.618 Millions	$ 16.923 Millions
Heron Therapeutics Inc	0.70	$ 64.643 Millions	$ 92.145 Millions
Amphastar Pharmaceuticals Inc	0.70	$ 331.903 Millions	$ 476.848 Millions
Axsome Therapeutics Inc	0.69	$ 319.850 Millions	$ 460.446 Millions
Zentalis Pharmaceuticals Inc	0.66	$ 24.783 Millions	$ 37.709 Millions
Pfizer Inc	0.64	$ 20,881.000 Millions	$ 32,646.000 Millions
Enanta Pharmaceuticals Inc	0.62	$ 33.419 Millions	$ 54.166 Millions
60 Degrees Pharmaceuticals Inc	0.61	$ 1.023 Millions	$ 1.685 Millions
Eton Pharmaceuticals Inc	0.59	$ 26.845 Millions	$ 45.124 Millions
Kura Oncology Inc	0.59	$ 70.242 Millions	$ 118.193 Millions
Allarity Therapeutics Inc	0.59	$ 16.982 Millions	$ 28.579 Millions
Bristol myers Squibb Company	0.59	$ 11,067.000 Millions	$ 18,659.000 Millions
Prestige Consumer Healthcare Inc	0.58	$ 89.127 Millions	$ 153.806 Millions
Biora Therapeutics Inc	0.57	$ 21.906 Millions	$ 38.687 Millions
Matinas Biopharma Holdings Inc	0.56	$ 0.761 Millions	$ 1.350 Millions
Karyopharm Therapeutics Inc	0.56	$ 75.225 Millions	$ 134.233 Millions
Journey Medical Corp	0.56	$ 25.643 Millions	$ 45.770 Millions
Nektar Therapeutics	0.55	$ 39.267 Millions	$ 70.985 Millions
Supernus Pharmaceuticals inc	0.52	$ 180.145 Millions	$ 347.378 Millions
Citius Oncology Inc	0.50	$ 16.564 Millions	$ 33.152 Millions
Verrica Pharmaceuticals Inc	0.50	$ 11.198 Millions	$ 22.442 Millions

Date modified: 2026-09-12T18:10:48+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.